Effects of V.II-BE on the number of circulating virus particles and immune cells in the blood in patients diagnosed positive with HIV

Documentation of the clinical effect and safety of V.II-BE on immunological parameters of HIV-infected patients: an open prospective trial

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

ISRCTN

Registry ID

ISRCTN83581730

Enrollment

Registered

2012-10-08

Start date

2012-06-01

Completion date

Unknown

Last updated

2015-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

HIV at a stage where antiviral treatment is not yet recommended according to medical guidelines Infections and Infestations Human immunodeficiency virus [HIV] disease

Interventions

All patients receive the V.II-BE solution (special extract of the medicinal plants chamomile, rose, lavender, myrrh, willow bark and spiny rush). The product contains 90% ethanol. The recommended dose

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Patients up to the age of 50 diagnosed with an HIV infection 2. Virus load below 50,000 copies/ml of blood 3. CD4 cell count above 350 cells/µl of blood 4. Stable virus load for the past 6 months

Exclusion criteria

Exclusion criteria: Patients cannot be included if: 1. They receive antiviral medication 2. They are treated with antibiotics 3. They undergo chemotherapy for cancer treatment 4. They have a background of abusing alcohol or illicit drugs 5. They have a co-infection with hepatitis 6. They are, in the case of women, pregnant or lactating

Design outcomes

Primary

Measure	Time frame
Virus load and CD4 cell count	—

Secondary

Measure	Time frame
Safety laboratory values	—

Countries

Romania

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026